


I hereby certify that this correspondence is being transmitted via Electronic Filing System to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 12, 2006

PATENT

Oksana Buynitzky
Date of Signature


October 12, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gonda et al.

Group Art Unit: Not Assigned

Serial No.: 10/550,533

Examiner: Not Assigned

Filed: September 23, 2005

Docket No.: 1386/21

For: METHOD FOR IDENTIFYING NUCLEIC ACID MOLECULES ASSOCIATED WITH ANGIOGENESIS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97, and 1.98, applicants' undersigned attorney brings to the attention of the Patent and Trademark Office the references listed on the attached form PTO-1449.

Copies of the references A-I as well as Form PTO-1449 are attached hereto as electronic files in PDF format. The electronic files of references A-I were divided into several parts to reduce the size of the attached files:

1. Reference A (WO02/086443) was broken into 2 parts;
2. Reference B (WO02/16439) was broken into 2 parts;

3. Reference C (WO03/010327) was broken into 3 parts;
4. Reference D (WO03/025138) was broken into 3 parts;
5. Reference E (WO03/039443) was broken into 9 parts;
6. Reference F (WO03/042661) was broken into 6 parts;
7. Reference G (WO03/058201) was broken into 3 parts;
8. Reference H (WO05/044981) was broken into 3 parts; and
9. Reference I (WO99/33982) was broken into 2 parts.

This is not to be construed as a representation that a search has been made or that a reference is relevant merely because cited.

Early passage of the subject application to issue is earnestly solicited.

The Commissioner is hereby authorized to charge any fees associated with the filing of this correspondence to Deposit Account No. 50-0426.

Respectfully submitted,

JENKINS, WILSON, TAYLOR & HUNT, P.A.

Date: October 12, 2006

By:



Arles A. Taylor, Jr.
Registration No. 39,395

Customer No.: 52354

1386/21 AAT/JD/omb
Enclosures

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 1 of 2		Attorney Docket No.: 1386/21

U.S. PATENT DOCUMENTS

Examin er Initials	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS

Examin er Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	A	WO 02/086443	10/31/2002	EOS Biotechnology, Inc.		
	B	WO 02/16439	02/28/2002	HYSEQ, Inc.		
	C	WO 03/010327	02/06/2003			
	D	WO 03/025138	03/27/2003	EOS Biotechnology, Inc.		

EXAMINER _____ DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office List of Documents Cited by Applicant	Application No.:	10/550,533
	Filing Date:	September 23, 2005
	First Named Inventor:	Gonda Thomas John
	Group:	TBA
	Examiner:	TBA
Page 2 of 2	Attorney Docket No.:	1386/21

	E	WO 03/039443	05/15/2003	Deutsches Krebsforschungszentrum; Ludwig-Maximilians Universität		
	F	WO 03/042661	05/22/2003	EOS Biotechnology, Inc.		
	G	WO 03/058201	07/17/2003	Quark Biotech, Inc; The Cleveland Clinic Foundation		
	H	WO 05/044981	5/19/2005	Sirna Therapeutics, Inc.		
	I	WO 99/33982	07/08/1999	Chiron Corporation; HYSEQ Inc.		

OTHER DOCUMENTS						
Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.				T

EXAMINER _____
 DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.